Showing results (1-10 of 118) with videos related to
Sort By:
Pageof 12
Current Opinion in Molecular Therapeutics|October 8, 2004
Gene-directed enzyme prodrug therapy: a current assessmentStephanie R McKeown, Claire Ward, Tracy RobsonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Evaluation of the antiangiogenic potential of AQ4NMartin O'Rourke, Claire Ward, Jenny Worthington, et al.Molecular Carcinogenesis|November 13, 2009
Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translationAndrea H Devlin, Paul Thompson, Tracy Robson, et al.Cardiovascular Research|September 17, 2005
Pericytes influence endothelial cell growth characteristics: role of plasminogen activator inhibitor type 1 (PAI-1)Marie McIlroy, Martin O'Rourke, Stephanie R McKeown, et al.International Journal of Cancer|May 31, 2008
Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotypeKarl T Butterworth, Helen O McCarthy, Andrea Devlin, et al.The Journal of Gene Medicine|February 16, 2005
A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4NVerna McErlane, Anita Yakkundi, Helen O McCarthy, et al.International Journal of Cancer|August 24, 2012
Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment responseLouise Ming, Niall M Byrne, Sarah Nicole Camac, et al.Cancer Gene Therapy|December 19, 2002
Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4NHelen O McCarthy, Anita Yakkundi, Verna McErlane, et al.Pharmacology & Therapeutics|February 9, 2018
Targeting cancer stem cells in the clinic: Current status and perspectivesStephanie Annett, Tracy RobsonThe Journal of Pharmacy and Pharmacology|January 18, 2007
Targeting nitric oxide for cancer therapyDavid Hirst, Tracy RobsonPageof 12